Multiple antigen peptide mimetics containing gp41 membrane-proximal external region elicit broad neutralizing antibodies against human immunodeficiency virus type 1 in guinea pigs
Lishuang Zhang
National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
Search for more papers by this authorLiang Miao
National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
Search for more papers by this authorXin Gong
National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
Search for more papers by this authorHuayan Zhang
National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
Search for more papers by this authorLan Yang
National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
Search for more papers by this authorYuhua Shi
National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
Search for more papers by this authorCorresponding Author
Wei Kong
National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
Correspondence to: Yaming Shan and Wei Kong, National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, 2699 Qianjin Street, Changchun, 130021, China. E-mail: [email protected]; [email protected]Search for more papers by this authorChunlai Jiang
National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
Search for more papers by this authorCorresponding Author
Yaming Shan
National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
Correspondence to: Yaming Shan and Wei Kong, National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, 2699 Qianjin Street, Changchun, 130021, China. E-mail: [email protected]; [email protected]Search for more papers by this authorLishuang Zhang
National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
Search for more papers by this authorLiang Miao
National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
Search for more papers by this authorXin Gong
National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
Search for more papers by this authorHuayan Zhang
National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
Search for more papers by this authorLan Yang
National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
Search for more papers by this authorYuhua Shi
National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
Search for more papers by this authorCorresponding Author
Wei Kong
National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
Correspondence to: Yaming Shan and Wei Kong, National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, 2699 Qianjin Street, Changchun, 130021, China. E-mail: [email protected]; [email protected]Search for more papers by this authorChunlai Jiang
National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
Search for more papers by this authorCorresponding Author
Yaming Shan
National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
Correspondence to: Yaming Shan and Wei Kong, National Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, 2699 Qianjin Street, Changchun, 130021, China. E-mail: [email protected]; [email protected]Search for more papers by this authorAbstract
Eliciting a broadly neutralizing antibody response against the HIV-1 membrane-proximal external region (MPER) mimicking the activity of 4E10 and 2F5 monoclonal antibodies remains a major challenge. In this study, two novel tetra-branched peptide immunogens, 4E10- and 2F5-MAP4, were designed and synthesized using a MAP system. Guinea pigs were immunized with either of these two synthetic immunogens emulsified in an oil-phase adjuvant at 3-week intervals. After four immunizations, epitope-specific antibody responses were induced successfully, and moderate neutralizing activities against tier 1 (clades B, BC, AE) and tier 2 (clade C) HIV-1 pseudoviruses were detectable in unfractionated sera and purified IgGs. The synthetic gp41 membrane-proximal external region peptide mimetics, 4E10- and 2F5-MAP4, assisted by an appropriate adjuvant, are promising prophylactic vaccine candidates potentially capable of eliciting broadly neutralizing antibody responses against HIV-1. Copyright © 2013 European Peptide Society and John Wiley & Sons, Ltd.
Supporting Information
Supporting information may be found in the online version of this article.
| Filename | Description |
|---|---|
| supplemental_data_Updated.docxWord 2007 document , 5.9 MB | Supporting information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1 Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 2001; 17: 1757–1765.
- 2 Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, Steindl F, Tauer C, Berger R, Barrett N, Jungbauer A, Katinger H. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 1994; 10: 1651–1658.
- 3 Nelson JD, Brunel FM, Jensen R, Crooks ET, Cardoso RM, Wang M, Hessell A, Wilson IA, Binley JM, Dawson PE, Burton DR, Zwick MB. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J. Virol. 2007; 81: 4033–4043.
- 4 Montero M, van Houten NE, Wang X, Scott JK. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 2008; 72: 54–84.
- 5 Gach JS, Leaman DP, Zwick MB. Targeting HIV-1 gp41 in close proximity to the membrane using antibody and other molecules. Curr. Top. Med. Chem. 2011; 11: 2997–3021.
- 6 Munoz-Barroso I, Salzwedel K, Hunter E, Blumenthal R. Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J. Virol. 1999; 73: 6089–6092.
- 7 Salzwedel K, West JT, Hunter E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J. Virol. 1999; 73: 2469–2480.
- 8 Suarez T, Gallaher WR, Agirre A, Goni FM, Nieva JL. Membrane interface-interacting sequences within the ectodomain of the human immunodeficiency virus type 1 envelope glycoprotein: putative role during viral fusion. J. Virol. 2000; 74: 8038–8047.
- 9 Saez-Cirion A, Nir S, Lorizate M, Agirre A, Cruz A, Perez-Gil J, Nieva JL. Sphingomyelin and cholesterol promote HIV-1 gp41 pretransmembrane sequence surface aggregation and membrane restructuring. J. Biol. Chem. 2002; 277: 21776–21785.
- 10 Poumbourios P, el Ahmar W, McPhee DA, Kemp BE. Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure. J. Virol. 1995; 69: 1209–1218.
- 11 Alfsen A, Iniguez P, Bouguyon E, Bomsel M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J. Immunol. 2001; 166: 6257–6265.
- 12 Coeffier E, Clement JM, Cussac V, Khodaei-Boorane N, Jehanno M, Rojas M, Dridi A, Latour M, El Habib R, Barre-Sinoussi F, Hofnung M, Leclerc C. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 2000; 19: 684–693.
- 13 Phogat S, Svehla K, Tang M, Spadaccini A, Muller J, Mascola J, Berkower I, Wyatt R. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology 2008; 373: 72–84.
- 14 Ye L, Wen Z, Dong K, Wang X, Bu Z, Zhang H, Compans RW, Yang C. Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines. PLoS One 2011; 6: e14813.
- 15 Arnold GF, Velasco PK, Holmes AK, Wrin T, Geisler SC, Phung P, Tian Y, Resnick DA, Ma X, Mariano TM, Petropoulos CJ, Taylor JW, Katinger H, Arnold E. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J. Virol. 2009; 83: 5087–5100.
- 16 Matyas GR, Wieczorek L, Beck Z, Ochsenbauer-Jambor C, Kappes JC, Michael NL, Polonis VR, Alving CR. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS 2009; 23: 2069–2077.
- 17 Julien JP, Bryson S, Nieva JL, Pai EF. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. J. Mol. Biol. 2008; 384: 377–392.
- 18 Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, Burton DR, Wilson IA. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005; 22: 163–173.
- 19 McGaughey GB, Barbato G, Bianchi E, Freidinger RM, Garsky VM, Hurni WM, Joyce JG, Liang X, Miller MD, Pessi A, Shiver JW, Bogusky MJ. Progress towards the development of a HIV-1 gp41-directed vaccine. Curr. HIV Res. 2004; 2: 193–204.
- 20 Ho J, Uger RA, Zwick MB, Luscher MA, Barber BH, MacDonald KS. Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response. Vaccine 2005; 23: 1559–1573.
- 21 McGaughey GB, Citron M, Danzeisen RC, Freidinger RM, Garsky VM, Hurni WM, Joyce JG, Liang X, Miller M, Shiver J, Bogusky MJ. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. Biochemistry 2003; 42: 3214–3223.
- 22 Brunel FM, Dawson PE. Synthesis of constrained helical peptides by thioether ligation: application to analogs of gp41. Chem. Commun. 2005; 20: 2552–2554.
- 23 Brunel FM, Zwick MB, Cardoso RM, Nelson JD, Wilson IA, Burton DR, Dawson PE. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J. Virol. 2006; 80: 1680–1687.
- 24 Sun ZY, Oh KJ, Kim M, Yu J, Brusic V, Song L, Qiao Z, Wang JH, Wagner G, Reinherz EL. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 2008; 28: 52–63.
- 25 Song L, Sun ZY, Coleman KE, Zwick MB, Gach JS, Wang JH, Reinherz EL, Wagner G, Kim M. Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface. Proc. Natl. Acad. Sci. U.S.A. 2009; 106: 9057–9062.
- 26 Kim M, Sun ZY, Rand KD, Shi X, Song L, Cheng Y, Fahmy AF, Majumdar S, Ofek G, Yang Y, Kwong PD, Wang JH, Engen JR, Wagner G, Reinherz EL. Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. Nat. Struct. Mol. Biol. 2011; 18: 1235–1243.
- 27 Liu J, Deng Y, Dey AK, Moore JP, Lu M. Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation. Biochemistry 2009; 48: 2915–2923.
- 28 Bryson S, Julien JP, Hynes RC, Pai EF. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications. J. Virol. 2009; 83: 11862–11875.
- 29 Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. USA 1988; 85: 5409–5413.
- 30 Tam JP, Zavala F. Multiple antigen peptide. A novel approach to increase detection sensitivity of synthetic peptides in solid-phase immunoassays. J. Immunol. Methods 1989; 124: 53–61.
- 31 Nardin EH, Oliveira GA, Calvo-Calle JM, Nussenzweig RS. The use of multiple antigen peptides in the analysis and induction of protective immune responses against infectious diseases. Adv. Immunol. 1995; 60: 105–149.
- 32 Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005; 79: 10108–10125.
- 33 Mascola JR, D'Souza P, Gilbert P, Hahn BH, Haigwood NL, Morris L, Petropoulos CJ, Polonis VR, Sarzotti M, Montefiori DC. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 2005; 79: 10103–10107.
- 34 Chen S, Cai W, He J, Vidal N, Lai C, Guo W, He H, Chen X, Fu L, Peeters M, Delaporte E, Andrieu JM, Lu W. Molecular epidemiology of human immunodeficiency virus type 1 in guangdong province of southern china. PLoS One 2012; 7: 7.
- 35 Nkolola JP, Peng H, Settembre EC, Freeman M, Grandpre LE, Devoy C, Lynch DM, La Porte A, Simmons NL, Bradley R, Montefiori DC, Seaman MS, Chen B, Barouch DH. Breadth of neutralizing antibodies elicited by stable, homogeneous clade a and clade C HIV-1 gp140 envelope trimers in guinea pigs. J. Virol. 2010; 84: 3270–3279.
- 36 Oscherwitz J, Yu F, Jacobs JL, Liu TH, Johnson PR, Cease KB. Synthetic peptide vaccine targeting a cryptic neutralizing epitope in domain 2 of Bacillus anthracis protective antigen. Infect. Immun. 2009; 77: 3380–3388.
- 37 Oscherwitz J, Yu F, Cease KB. A heterologous helper T-cell epitope enhances the immunogenicity of a multiple-antigenic-peptide vaccine targeting the cryptic loop-neutralizing determinant of Bacillus anthracis protective antigen. Infect. Immun. 2009; 77: 5509–5518.
Citing Literature
